Autoimmune Disease Program

About Carisma Therapeutics

Carisma Therapeutics is a pioneer in macrophage-based cell therapy, founded as a spin-out from the University of Pennsylvania. Its mission is to develop engineered CAR-Macrophage and CAR-Monocyte therapies to treat solid tumors and other serious diseases by harnessing cells that naturally infiltrate and remodel hostile tissue microenvironments. The company's strategy centers on advancing its lead anti-HER2 candidate, CT-0508, through Phase 1 trials while expanding its modular platform into new targets and indications, supported by experienced leadership and key academic collaborations. Carisma became a public company via a merger in March 2023.

About The MT Group

The MT Group is a specialized biospecimen CRO with over 20 years of experience, providing critical research materials and services to the life sciences industry. The company differentiates itself through its 'MT Level' metadata, offering deeply annotated biospecimens linked to comprehensive clinical data, which is essential for robust translational and diagnostic research. Its business model is built on custom collection projects, a vast site network, and a partnership-oriented approach that drives significant repeat business from global biopharma and diagnostic clients. While privately held and service-based, it plays a foundational role in the R&D value chain by addressing the pre-analytical variable challenges in assay and therapeutic development.

Therapeutic Areas

Other Autoimmune Disease Drugs